Murat Tolga AVŞAR, Resmiye Nur OKUDAN, Zeynep Zehra GÜMÜŞ, Rumeysa SAMANCİ

Efficacy of Prolotherapy With Periarticular 5% Dextrose In The Treatment of Knee Joint Osteoarthritis

Objective: Determination of the effectiveness of periarticular 5% dextrose prolotherapy in the treatment of knee pain due to osteoarthritis.Material and Methods: The clinical results of prolotherapy with 5% periarticular dextrose in adult female and male patients with knee pain and complaints related to osteoarthritis were evaluated retrospectively. During the examination, we identified the sensitive ligaments in the knee and injected 1 cc of 5% dextrose with a 0.6 * 60 mm sterican needle. In routine practice, stretching exercises are recommended to patients after prolotherapy and for analgesia, a combined analgesic containing paracetemol 500mg + codeine phosphate 10mg + caffeine 30mg is given for the first 3 days. In addition to the initial application, prolotherapy is performed 3 times with an interval of 20 days, and when the Visual Analogue Scale (VAS) score decreases by 80% or more after the first or second injection, prolotherapy is terminated. Results: 30 patients aged between 36-70 years were included in the study. Patients’ mean age was 52,9±9,0 years. Nineteen patients received 3 sessions and 11 patients received 2 sessions of prolotherapy. A significant decrease was achieved in VAS scores of all patients except one patient. The VAS score was 2.9 at the end of the third session meanwhile the initial VAS average was 8.4. None of the patients had any side effects that would terminate the treatment.Conclusion: The data obtained in the study show that prolotherapy with periarticular 5% dextrose is effective in the treatment of knee pain and complaints related to osteoarthritis. However, more comprehensive studies will be guiding the clarification of its place in the osteoarthritis’ treatment.

Keywords:

Prolotherapy Knee, Osteoarthritis, Periarticular 5% dextrose, Visual Analog Scale,

PDF

___

REFERENCES 1.Felson DT. Osteoarthritis of theknee. N Engl J Med. 2006;354(8):841–8.
2.Woo J, Leung J, Lau E. Prevalence and correlates of musculoskeletal pain in Chineseelderlyandtheimpact on 4-year physical function and quality of life. PublicHealth. 2009;123(8):549–56.
3.Sayer EC, Li LC, Kopec JA, Esdaile JM, Cibere J. Theeffect of disease site (knee, hip, hand, foot, lowerbackorneck) on employment due to osteoarthritis. Plos one. 2010; 5(5): e10470
4.Hawker GA, Gignac MA, Badley E, et al. A longitudinal study to explainthe pain-depression link in older adults with osteoarthritis. ArthritisCare&Res. 2011;63(10):1382–90
5.Hutton I, Gamble G, Mclean G, Butcher H, Gow P, Dalbeth N. Obstaclestoaction in arthritis: a communitycase-controlstudy. Int J RheumDis. 2009;12(2):107–17.
6.Samson DJ, Grant MD, Ratko TA, Bonnell CJ, Ziegler KM, Aronson N. Treatment of primary and secondar yosteoarthritis of the knee. EvidRepTechnolAssess (Full Rep). 2007; (157):1-157.
7.Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of RheumatologySubcommittee on Osteoarthritis Guidelines. ArthritisRheum. 2000 ;43(9):1905-15.
8.Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. AmericanCollege of Rheumatology 2012 recommendations for the use of non pharmacologic and pharmacologic therapies in osteoarthritis of thehand, hip, and knee. ArthritisCareRes (Hoboken). 2012 ;64(4):465-74.
9.Felson DT. Osteoarthritis: prioritiesforosteoarthritisresearch: muchto be done. NatRevRheumatol. 2014;10(8):447-8.
10.Kim WJ, Shin HY, Koo GH, Park HG, Ha YC, Park YH. Ultrasound-guided Prolotherapy with Polydeoxyribonucleotide Sodium in Ischiofemoral Impingement Syndrome. PainPract. 2014 ;14(7):649-55.
11.Solmaz İ, Akpancar S, Örsçelik A, Yener-Karasimav Ö, Gül D. Dextrose injections for failed backsurgery syndrome: a consecutive case series. EurSpine J. 2019 ;28(7):1610-1617.
12.Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A SystematicReview of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. ClinMedInsights Arthritis Musculoskelet Disord. 2016 ;9:139-59.
13.Rabago D, Nourani B. ProlotherapyforOsteoarthritisandTendinopathy: a DescriptiveReview. CurrRheumatolRep. 2017 ;19(6):34.
14.Rahimzadeh P, Imani F, Faiz SH, Alebouyeh MR, Azad-Ehyaei D, Bahari L, et al. Adding Intra-Articular Growth Hormone to PlateletRichPlasma under UltrasoundGuidance in Knee Osteoarthritis: A ComparativeDouble-BlindClinical Trial. AnesthPainMed. 2016;6(6):e41719.
15.Hussain SM, Neilly DW, Baliga S, Patil S, Meek R. Kneeosteoarthritis: a review of management options. ScottMed J. 2016 ;61(1):7-16.
16.Yoshii, Y. et al. Efects of multiple injections of hypertonic dextrose in the rabbit carpal tunnel: a potential model of carpal tunnel syndrome development. Hand (N.Y.) 2014;9(1):52-7.
17.Reeves KD, Sit RW, Rabago DP. DextroseProlotherapy: A NarrativeReview of Basic Science, Clinical Research, and Best Treatment Recommendations. PhysMedRehabilClin N Am. 2016 ;27(4):783-823.
18.Lyftogt J. Subcutaneousprolotherapytreatment of refractory knee, shoulder and lateral elbow pain. AustMusculoskeletal Med. 2007;12(2):110–112.
19.Rezasoltani Z, Taheri M, Mofrad MK, Mohajerani SA. Periarticular dextrose prolotherapy instead of intra Articular injection for pain and functional improvement in knee osteoarthritis. J PainRes. 2017;10:1179-1187.
20.Seven MM, Ersen O, Akpancar S, Ozkan H, Turkkan S, Yıldız Y, et al. Effectiveness of prolotherapy in thetreatment of chronic rotatorcuff lesions. Orthop Traumatol Surg Res. 2017;103(3):427-433.
21.Sit RWS, Wu RWK, Reeves KD, Rabago D, Chan DCC, Yip BHK, et al. Efficacy of intra-articular hypertonic dextrose prolotherapy versus normal saline for kneeosteoarthritis: a protocolfor a triple-blinded randomized controlledtrial. BMC ComplementAlternMed. 2018;18(1):157.
22.Rabago D, Zgierska A, Fortney L, Kijowski R, Mundt M, Ryan M, et al. Hypertonic dextrose injections (prolotherapy) for knee osteoarthritis: results of a single-armun controlled study with 1-year follow-up. J Altern Complement Med. 2012 ;18(4):408